INCY Incyte Corp.

$INCY that huge third quarter research line is mostly one accounting decision, and the filing shows the split. Of the 1.267 billion dollars in total consideration for Vega, 1.232 billion dollars went to the latarcibart asset and was expensed in full during the quarter because the acquired in process research had no alternative future use, leaving just 35.3 million dollars allocated to everything else. The extra 750 million dollars Star can earn sits off the income statement entirely until the United States sales milestones are actually met.

$INCY Can growth outside Jakafi carry Incyte's raised $5,210M–$5,300M 2026 sales guide? 🚀 Incyte, maker of the blood-cancer pill Jakafi, raised its 2026 net sales guide to $5,210M–$5,300M from $5,130M–$5,260M, and its market value was about $23.35B at $116.87 at 16:00 ET on October 28, 2026 ⚠️ The raised Opzelura guide of $1,100M–$1,120M includes a one-time $246M benefit from the CMS rebate settlement, while the Jakafi guide stayed at $3,220M–$3,270M after Q3 Jakafi sales grew only 4% to $827M ⚠️ With $3,909M of net sales already booked in the first nine months, the new guide implies Q4 net sales of about $1,301M–$1,391M, so its low end is below Q3's $1,316M 📈 Cash and marketable securities still rose to $3.9B at September 30 from $3.6B at the end of 2025, even after the $1.25B Vega purchase 📅 Next: Q4 2026: Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in HS, plus an EU decision on povorcitinib Source: Incyte Q3 2026 release, SEC 8-K, Oct 29

$INCY reported earnings before the open: adjusted EPS of −$3.60 vs. −$3.93 estimated, a beat of 8.4%. I used Stock Meadow to review the results.

$INCY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.60 down -259.29% YoY • Reported revenue of $1.56B up 14.00% YoY • Incyte raised full-year 2026 net sales guidance to $5.21B, Opzelura to $1.1B, and Hematology and Oncology to $890M, while reaffirming guidance for all other categories.

$INCY reports earnings tomorrow before the open. I used Stock Meadow’s earnings dashboard to review its history: INCY has beaten EPS estimates in 5 of its last 8 reports.

$INCY showed up on our Buy the Dip scan: weekly up, daily pulled back, 4H flipped back up. 1W: bullish since 06/01 (+10.5%) 1D: bearish since 09/29 (-8.2%) 4H: flipped bullish 10/21 Price is 0.8% under the 4H flip, and the daily and weekly clouds are grey. On the radar, nothing more.

$INCY brought new ESMO data in gastrointestinal tumors (pancreas and colorectal). Q3 results are due October 29.

$INCY $WELL Two slow ones from early Oct: $INCY 112.98 to 114.73 over 8 days, $WELL 224.24 to 228.42 over 5. Neither was exciting. Swing trading large caps is mostly waiting. The money is in not forcing entries on days with no setup.

$INCY Latest analyst update, Oct 21, 2026: TD Cowen kept Buy and raised its price target on Incyte to 140 USD from 138 USD. Third-party analyst opinion. More details in our $INCY stock hub. Not investment advice.

$INCY: BUY alert went out Oct 5 after the close at $112.98. Sold Oct 15 at $114.86, +1.66% in 8 trading days. A boring, steady biotech worked better than the exciting names this month.

Latest company news, October 18, 2026: Incyte will present four rapid oral abstracts at ESMO 2026 (October 23-26) and hold an investor event on October 26, 2:30-4:00 p.m. ET. Incyte $INCY Stock Hub: Atebrioz Approval And The 2028 Cliff Deeper dive in our hub. Not investment advice.

$INCY Incyte slipped about 3.9% after hours on the Syndax IPF miss, and the scale here is just different. Axatilimab is Niktimvo in chronic GVHD, already approved, and it did 60.3 million dollars of net sales in Q2, up 67% YoY. That is roughly 4% of Incyte's 1.49 billion dollars in total Q2 net sales. IPF was expansion optionality on top of an approved product, not an existing revenue line, and the chronic GVHD studies are still running.